A case of advanced medullary thyroid carcinoma successfully treated with sunitinib

Oncologist

Volumn 14, Issue 11, 2009, Pages 1083-1087

  Bugalho, Maria João ^a,b   Domingues, Rita ^a   Borges, Alexandra ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b NOVA MEDICAL SCHOOL   (Portugal)

Author keywords

Carcinoma; Sunitinib; Thyroid

Indexed keywords

CALCITONIN; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB;

ADULT; ADVANCED CANCER; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; CALCITONIN BLOOD LEVEL; CANCER GROWTH; CASE REPORT; DISEASE ASSOCIATION; DRUG EFFICACY; GENE MUTATION; GLOSSITIS; HISTOPATHOLOGY; HUMAN; MALE; METASTASIS; MOLECULAR GENETICS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SIDE EFFECT; THYROID FUNCTION; THYROID MEDULLARY CARCINOMA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR REGRESSION;

ANTINEOPLASTIC AGENTS; CARCINOMA, MEDULLARY; HUMANS; INDOLES; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-RET; PYRROLES; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 75449104629     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0195     Document Type: Article

References (20)

1. Eng C, Clayton D, Schuffenecker I et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 1996;276:1575-1579.
2. Wohllk N, Cote GJ, BugalhoMMet al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 1996;81:3740-3745.
3. Romei C, Elisei R, Pinchera A et al. Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 1996;81:1619-1622.
4. Moura MM, Cavaco BM, Pinto AE et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009;100:1777-1783.
5. Chow LQM, Eckhardt SG. Sunitinib: From rational design to clinical efficacy. J Clin Oncol 2007;25:884-896.
6. Mendel DB, Laird AD, Xin X et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
7. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-766.
8. Faivre S, Delbaldo C, Vera K et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
9. Rini BI. Sunitinib. Expert Opin Pharmacother 2007;8:2359-2369.
10. Escudier B, Roigas J, Gillessen S et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 2009;27:4068-4075.
11. Kim DW, Jo YS, Jung HS et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-4076.
12. Kelleher FC, McDermott R. Response to sunitinib in medullary thyroid cancer. Ann Intern Med 2008;148:567.
13. Dawson SJ, Conus NM, Toner GC et al. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma. Anticancer Drugs 2008;19:547-552.
14. Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol 2008;26(15 suppl):6025.
15. de Groot JWB, Links TP, Plukker JTM et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006;27:535-560.
16. Sherman SI. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab 2009;94:1493-1499.
17. Schlumberger MJ, Elisei R, Bastholt L et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27:3794-3801.
18. Carlomagno F, Vitagliano D, Guida T et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62:7284 -7290.
19. Sathornsumetee S, Rich JN. Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy. Drugs Today (Barc) 2006;42:657-670.
20. Akeno-Stuart N, Croyle M, Knauf JA et al. The RET kinase inhibitor NVPAST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res 2007;67:6956-6964.